Celaid Therapeutics Inc. completed the second close of its Series B financing round, raising JPY 400 million (approximately USD 2.6 million) with new investors Shionogi & Co., Ltd. and Teikoku Ventures, Inc.
PRIVATEOct 05, 2026
Amount Raised
$2.6 Million
Round Type
Seed
BunkyoBiotechnologyTherapeutics
Investors
Teikoku Ventures, Inc.Shionogi & Co., Ltd.
Description
Celaid Therapeutics Inc. has completed the second close of its Series B financing round, raising a total of JPY 400 million (approximately USD 2.6 million). This funding will support U.S. clinical trial preparations for their product CLD-001
Company Information
Company
Celaid Therapeutics
Location
Bunkyo, Tokyo, Japan
About
Celaid Therapeutics Inc. is a startup born out of the University of Tokyo and University of Tsukuba with proprietary technology for selective ex vivo HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapies targeting hematologic and genetic diseases, ex vivo HSC gene therapies for genetic disorders, and angiogenesis for ischemic diseases.
Fundz sees it the moment Celaid Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BunkyoBiotechnologyTherapeutics